Michael L Maitland

6PUBLICATIONS
46CO-AUTHORS
Molecular targetsDisease surveillanceCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 03, 2025
Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).

Emily K Bergsland, Susan Geyer, Timothy R Asmis

|Jun 04, 2025
Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities.

Sanja Karovic, Erik Dvergsten, Chiara Pierattini

|Apr 27, 2023
Model-based approach to identify predictors of paclitaxel-induced myelosuppression in "real-world" administration.

Ahmed M Salem, Erik Dvergsten, Sanja Karovic

|Jan 03, 2023
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.

René Bruno, Mathilde Marchand, Kenta Yoshida

|Jun 04, 2021
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.

Michael L Maitland, Jasgit C Sachdev, Manish R Sharma

Pageof 1